INCREASED PLASMA LEVEL OF D-DIMER AS A MARKER OF HIGH ARTERIAL THROMBOSIS RISK
https://doi.org/10.20996/1819-6446-2008-4-4-80-84
Abstract
Estimation of cardiovascular risk is discussed. Serum lipoproteins, glucose, fibrinogen, von Willebrand factor, tissue-type plasminogen activator, C-reactive protein etc are offered for use as laboratory indicators. At the same time new markers of high cardiovascular risk are under development. D-dimer is a product of fibrin degradation and its plasma level reflects intensity of intravascular thrombosis and fibrinolysis. Plasma level of D-dimer as a tool for estimation of cardiovascular risk and pharmacotherapy efficacy is discussed.
About the Authors
N. V. Furman
Saratov Research Institute of Cardiology of Rosmedtechnology, Chernyshevsky ul. 141, Saratov, 410028, Russia
Russian Federation
Russian Federation
N. F. Puchinjan
Saratov Research Institute of Cardiology of Rosmedtechnology, Chernyshevsky ul. 141, Saratov, 410028, Russia
Russian Federation
Russian Federation
O. M. Ansimova
Saratov Research Institute of Cardiology of Rosmedtechnology, Chernyshevsky ul. 141, Saratov, 410028, Russia
Russian Federation
Russian Federation
P. J. Dovgalevsky
Saratov Research Institute of Cardiology of Rosmedtechnology, Chernyshevsky ul. 141, Saratov, 410028, Russia
Russian Federation
Russian Federation
References
1. Оганов Р.Г., Масленникова Г.Я. Профилактика сердечно-сосудистых и других неинфекционных заболеваний – основа улучшения демографической ситуации в России. Кардиоваск тер профилакт. 2005;3(1):4-9.
2. Murray C.J., Lopez A.D. Global mortality, disability, and contribution of risk factors: global burden of disease study. Lancet. 1997;349:1436-42.
3. Оганов Р.Г., Погосова Г.В. Современные стратегии профилактики и лечения сердечно-сосудистых заболеваний. Кардиология. 2007;(12):4-9.
4. World Health Organization. Prevention of cardiovascular disease: pocket guidelines for assessment and management of cardiovascular risk : (WHO/ISH cardiovascular risk prediction charts for the European Region). Avaiable at http://whqlibdoc.who.int/publications/2007/ 9789241547260_eng.pdf
5. Wilson P.W., D’Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–47.
6. Hennekens C.H. Increasing burden of cardiovascular disease. Current knowledge and future directions for research on risk factors. Circulation. 1998;97(11):1095-102.
7. Zafiris J.H. Atherosclerosis, thrombosis, and inflammatory risk factors, from history and the laboratory to real life. Eur Heart J. 2005;26(4):317-8.
8. Yarnell J.W.G., Patterson C.C., Sweetnam P.M., et al. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J. 2004; 25(12): 1049-56.
9. Оганов Р.Г. Факторы риска сердечно-сосудистых заболеваний. В. Болезни сердца: руководство для врачей. Под ред. Оганова Р.Г. и Фоминой И.Г., М.: Литтерра. 2006. С. 35-72.
10. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355:2615-7.
11. Wang T.J., Gona P., Larson M.G. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.
12. Smulders Y.M., Thijs A., Twisk J.W. New cardiovascular risk determinants do exist and are clinically useful. Eur Heart J. 2008;29:436–40.
13. Wang T.J. New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J. 2008;29:441–4.
14. Панченко Е.П., Добровольский А.Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М.: Спорт и культура; 1999.
15. Панченко Е.П. Концепция атеротромбоза – основа патогенеза сердечно–сосудистых заболеваний. Основные направления антитромботической терапии. РМЖ. 2005;7(13): 433-40.
16. Баркаган З.С., Момот А.П. Основы диагностики нарушений гемостаза. М.: Ньюдиамед, 1999.
17. Панченко Е.П., Добровольский А.Б. Возможности диагностики нарушений гемоста- за и перспективные направления антитромботической терапии при ишемической бо- лезни сердца. Кардиология. 1996;(5):4-10.
18. Komarov A., Panchenko E., Dobrovolsky A., et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J. 2002;23:1309-16.
19. Никитин А.В., Ипатов П.В., Фурсов А.Н. и др. Тромбоэмболия легочной артерии и тромбофилии: оптимизация диагностики и лечения. Клин мед. 2006,(6):21-4.
20. Папаян Л. П., Князева Е. С. D-димер в клинической практике: Пособие для врачей. М.: Инсайт полиграфик, 2002.
21. Fancher T.L., White R.H., Kravitz R.L. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ. 2004;329:821-4.
22. Wakai A., Gleeson A., Winter D. Role of fibrin D-dimer testing in emergency medicine. Emerg Med J 2003;20:319–25.
23. Федоткина Ю.А., Добровольский А.Б., Кропачева Е.С. и др. Диагностическое и прогностическое значение D-димера в клинике внутренних болезней. Тер арх. 2003,(12):66-9.
24. Task Force Report. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J. 2000;21:1301–36.
25. Palareti G., Cosmi B., Legnani C., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-9.
26. Andreotti F., Becker R.C. Atherothrombotic disorders: new insights from hematology. Circulation. 2005;111:1855-63.
27. Danesh J., Whincup P., Walker M., et al. Fibrin D-dimer and coronary heart disease. prospective study and meta-analysis. Circulation. 2001;103:2323-7.
28. Ridker P.M., Hennekens C.H., Cerskus A., Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-40.
29. Koenig W., Rothenbacher D., Hoffmeister A. et al. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol. 2001;21:1701-5.
30. Mills J.D., Mansfield M.W., Grant P.J. Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 2002;22:704-9.
31. Tataru M.-C., Heinrich J., Junker R., et al. D-dimer in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J. 1999;20:1493- 502
32. Yarnell J., McCrum E., Rumley A., et al. Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study. Eur Heart J. 2005;26:332-42.
33. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-8.
34. Moss A.J., Goldstein R.E., Marder V.J., et al. Thrombogenic factors and recurrent coronary events. Circulation. 1999; 99:2517-22.
35. Yarnell J.W., Sweetnam P.M., Rumley A., Lowe G.D. Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. Arterioscler Thromb Vasc Biol. 2000;20:271-9.
36. Lowe G.D., Yarnell J.W., Rumley A., et al. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol. 2001;21(4):603-10.
37. Folsom A.R., Aleksic N., Park E., et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21:611-7.
38. Oldgren J., Linder R., Grip L., et al. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21: 1059-64.
39. Feinberg W.M., Pearce L.A., Hart R.G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-53.
40. Kamath S., Blann A.D., Chin B.S., et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J. 2002;23:1788-95.
41. Napoli D.M., Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke. 2002;33:1763-71.
42. Woodward M., Lowe G.D.O., Campbell D.J., et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-7.
43. Barber M., Langhorne P., Rumley A., et al. D-dimer predicts early clinical progression in ischemic stroke. Stroke. 2006;37:1113-5.
44. Арутюнов Г.П., Розанов А.В. Тенектеплаза. Первый опыт применения в Российской Фе- дерации. Сердце. 2006; 5(6):284-6.
45. Christersson C., Oldgren1 J., Bylock A., et al. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. Eur Heart J. 2007;28:692–8.
46. Диагностика и лечение в кардиологии. Под редакцией Майкла Х. Кроуфода; Пер. с англ.. М.: Медпресс-информ; 2007.
Review
For citations:
Furman N.V., Puchinjan N.F., Ansimova O.M., Dovgalevsky P.J. INCREASED PLASMA LEVEL OF D-DIMER AS A MARKER OF HIGH ARTERIAL THROMBOSIS RISK. Rational Pharmacotherapy in Cardiology. 2008;4(4):80-84. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-80-84
Views:
1213
Email this article 